151 related articles for article (PubMed ID: 19577359)
1. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells.
Rachner TD; Singh SK; Schoppet M; Benad P; Bornhäuser M; Ellenrieder V; Ebert R; Jakob F; Hofbauer LC
Cancer Lett; 2010 Jan; 287(1):109-16. PubMed ID: 19577359
[TBL] [Abstract][Full Text] [Related]
2. Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells.
Ma YG; Liu WC; Dong S; Du C; Wang XJ; Li JS; Xie XP; Wu L; Ma DC; Yu ZB; Xie MJ
PLoS One; 2012; 7(5):e37451. PubMed ID: 22655048
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
[TBL] [Abstract][Full Text] [Related]
4. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
[TBL] [Abstract][Full Text] [Related]
5. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
6. Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
Jeong J; Lee KS; Choi YK; Oh YJ; Lee HD
J Korean Med Sci; 2011 Dec; 26(12):1569-75. PubMed ID: 22147993
[TBL] [Abstract][Full Text] [Related]
7. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
9. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
[TBL] [Abstract][Full Text] [Related]
11. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.
Senaratne SG; Mansi JL; Colston KW
Br J Cancer; 2002 May; 86(9):1479-86. PubMed ID: 11986784
[TBL] [Abstract][Full Text] [Related]
12. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates induce breast cancer cell death in vitro.
Fromigue O; Lagneaux L; Body JJ
J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
[TBL] [Abstract][Full Text] [Related]
14. Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.
Park YE; Bava U; Lin JM; Cornish J; Naot D; Reid IR
Calcif Tissue Int; 2019 Nov; 105(5):497-505. PubMed ID: 31324954
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
[TBL] [Abstract][Full Text] [Related]
17. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
Tannehill-Gregg SH; Levine AL; Nadella MV; Iguchi H; Rosol TJ
Clin Exp Metastasis; 2006; 23(1):19-31. PubMed ID: 16715352
[TBL] [Abstract][Full Text] [Related]
18. Mechanical loading influences the effects of bisphosphonates on human periodontal ligament fibroblasts.
Jacobs C; Walter C; Ziebart T; Dirks I; Schramm S; Grimm S; Krieger E; Wehrbein H
Clin Oral Investig; 2015 Apr; 19(3):699-708. PubMed ID: 25055746
[TBL] [Abstract][Full Text] [Related]
19. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.
Brown HK; Ottewell PD; Coleman RE; Holen I
J Cell Mol Med; 2011 Mar; 15(3):501-13. PubMed ID: 20015195
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis.
Weichhaus M; Segaran P; Renaud A; Geerts D; Connelly L
Cancer Med; 2014 Oct; 3(5):1112-25. PubMed ID: 24976340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]